OptimizeRx Past Earnings Performance
Past criteria checks 0/6
OptimizeRx's earnings have been declining at an average annual rate of -52.3%, while the Healthcare Services industry saw earnings growing at 5.7% annually. Revenues have been growing at an average rate of 23.6% per year.
Key information
-52.3%
Earnings growth rate
-48.2%
EPS growth rate
Healthcare Services Industry Growth | 1.7% |
Revenue growth rate | 23.6% |
Return on equity | -13.9% |
Net Margin | -24.6% |
Next Earnings Update | 14 May 2024 |
Recent past performance updates
Recent updates
OptimizeRx Corporation's (NASDAQ:OPRX) 36% Jump Shows Its Popularity With Investors
Jan 09Analyst Forecasts Just Became More Bearish On OptimizeRx Corporation (NASDAQ:OPRX)
Aug 24OptimizeRx Corporation (NASDAQ:OPRX) Shares May Have Slumped 38% But Getting In Cheap Is Still Unlikely
Aug 16Is Now An Opportune Moment To Examine OptimizeRx Corporation (NASDAQ:OPRX)?
May 31OptimizeRx: A Top Candidate For My Speculative 'Bio Boom' Portfolio
Oct 12Is Now The Time To Look At Buying OptimizeRx Corporation (NASDAQ:OPRX)?
Sep 23OptimizeRx extends reach with Cooler Screens Partnership
Jul 26OptimizeRx: A Small-Cap Digital Health Technology Gem With Near-Term Inflection In Profitability
Jun 27The Strong Earnings Posted By OptimizeRx (NASDAQ:OPRX) Are A Good Indication Of The Strength Of The Business
Nov 16Why We Think OptimizeRx Corporation's (NASDAQ:OPRX) CEO Compensation Is Not Excessive At All
Aug 13A Look At The Fair Value Of OptimizeRx Corporation (NASDAQ:OPRX)
Jul 15Here's Why We're Not At All Concerned With OptimizeRx's (NASDAQ:OPRX) Cash Burn Situation
Jun 24Investors Will Want OptimizeRx's (NASDAQ:OPRX) Growth In ROCE To Persist
May 10Estimating The Fair Value Of OptimizeRx Corporation (NASDAQ:OPRX)
Mar 29Don't Ignore The Fact That This Insider Just Sold Some Shares In OptimizeRx Corporation (NASDAQ:OPRX)
Feb 21What Percentage Of OptimizeRx Corporation (NASDAQ:OPRX) Shares Do Insiders Own?
Jan 27Revenue & Expenses BreakdownBeta
How OptimizeRx makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 72 | -18 | 54 | 0 |
30 Sep 23 | 63 | -14 | 51 | 0 |
30 Jun 23 | 62 | -14 | 52 | 0 |
31 Mar 23 | 62 | -14 | 52 | 0 |
31 Dec 22 | 62 | -11 | 49 | 0 |
30 Sep 22 | 63 | -10 | 46 | 0 |
30 Jun 22 | 64 | -7 | 43 | 0 |
31 Mar 22 | 64 | -3 | 39 | 0 |
31 Dec 21 | 61 | 0 | 33 | 0 |
30 Sep 21 | 57 | 1 | 30 | 0 |
30 Jun 21 | 52 | 1 | 26 | 0 |
31 Mar 21 | 47 | -1 | 23 | 0 |
31 Dec 20 | 43 | -2 | 23 | 0 |
30 Sep 20 | 34 | -6 | 22 | 0 |
30 Jun 20 | 29 | -7 | 21 | 0 |
31 Mar 20 | 27 | -5 | 20 | 0 |
31 Dec 19 | 25 | -3 | 17 | 0 |
30 Sep 19 | 24 | -1 | 15 | 0 |
30 Jun 19 | 24 | 1 | 13 | 0 |
31 Mar 19 | 22 | 0 | 12 | 0 |
31 Dec 18 | 21 | 0 | 11 | 0 |
30 Sep 18 | 19 | 0 | 10 | 0 |
30 Jun 18 | 16 | -1 | 9 | 0 |
31 Mar 18 | 14 | -1 | 8 | 0 |
31 Dec 17 | 12 | -2 | 7 | 0 |
30 Sep 17 | 10 | -2 | 7 | 0 |
30 Jun 17 | 9 | -2 | 6 | 0 |
31 Mar 17 | 8 | -2 | 6 | 0 |
31 Dec 16 | 8 | -2 | 6 | 0 |
30 Sep 16 | 7 | -2 | 2 | 0 |
30 Jun 16 | 8 | -1 | 1 | 0 |
31 Mar 16 | 7 | -1 | 1 | 0 |
31 Dec 15 | 7 | -1 | 1 | 0 |
30 Sep 15 | 7 | 0 | 1 | 0 |
30 Jun 15 | 7 | 0 | 1 | 0 |
31 Mar 15 | 7 | 0 | 1 | 0 |
31 Dec 14 | 7 | -1 | 1 | 0 |
30 Sep 14 | 6 | -1 | 1 | 0 |
30 Jun 14 | 6 | -1 | 1 | 0 |
31 Mar 14 | 5 | -1 | 1 | 0 |
31 Dec 13 | 5 | 0 | 1 | 0 |
30 Sep 13 | 4 | 0 | 4 | 0 |
30 Jun 13 | 3 | 0 | 3 | 0 |
Quality Earnings: OPRX is currently unprofitable.
Growing Profit Margin: OPRX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: OPRX is unprofitable, and losses have increased over the past 5 years at a rate of 52.3% per year.
Accelerating Growth: Unable to compare OPRX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: OPRX is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (15.4%).
Return on Equity
High ROE: OPRX has a negative Return on Equity (-13.88%), as it is currently unprofitable.